Dataset Information


Residual Risk of Atherosclerotic Cardiovascular Events in Relation to Reductions in Very-Low-Density Lipoproteins.

ABSTRACT: It is uncertain whether pharmacological reductions in very-low-density lipoproteins (VLDLs), and their component triglyceride and cholesterol could reduce residual risk of atherosclerotic cardiovascular disease (ASCVD) events among individuals in whom low-density lipoprotein cholesterol (LDL-C) has been adequately lowered. We examined whether individuals with greater on-statin reductions in VLDL-related measures-beyond reductions in LDL-C-were at further reduced risk of ASCVD.In 9423 participants in the JUPITER (Justification for the Use of Statins in Prevention) trial (NCT00239681), at baseline and on statin we measured standard lipids, 400-MHz proton nuclear magnetic resonance spectroscopy-measured VLDL particle subclasses (small, medium, and large VLDL lipoprotein particle concentration), and total VLDL cholesterol mass. Compared with individuals allocated to placebo, we examined risk of incident ASCVD (N=211) among statin-allocated participants who achieved minimal (


PROVIDER: S-EPMC5779048 | BioStudies | 2017-01-01

REPOSITORIES: biostudies

Similar Datasets

2017-01-01 | S-EPMC5586287 | BioStudies
2015-01-01 | S-EPMC4618030 | BioStudies
2021-01-01 | S-EPMC7802592 | BioStudies
2019-01-01 | S-EPMC6940163 | BioStudies
2019-01-01 | S-EPMC7019317 | BioStudies
2019-01-01 | S-EPMC6615056 | BioStudies
2015-01-01 | S-EPMC4674425 | BioStudies
2019-01-01 | S-EPMC6842201 | BioStudies
1000-01-01 | S-EPMC5855932 | BioStudies
2016-01-01 | S-EPMC5074319 | BioStudies